Inhibition of arterial thrombotic occlusion or thromboembolism
AssigneeScripps Clinic and Research Foundation
InventorsJohn H. Griffin, Andras Gruber, Stephen R. Hanson, Lawrence A. Harker
Life of this patent
Estimating the term…
Abstract
The method of preventing arterial thrombotic occlusion or thromboembolism by administering plasma-derived or recombinant produced protein C alone or in combination with a thrombolytic agent or combinations of thrombolytic agents.
Claims14
A pharmaceutical composition for inhibiting arterial platelet deposition, acute arterial thrombotic occlusion, thromboembolism, or stenosis in coronary, cerebral or peripheral arteries or in vascular grafts the composition comprising an effective amount of isolated and purified activated protein C obtained from a plasma source, to inhibit arterial platelet deposition, acute arterial thrombotic occlusion, thromboembolism or stenosis in coronary, cerebral or peripheral arteries or in vascular grafts in a pharmaceutically acceptable carrier.
A pharmaceutical composition for inhibiting arterial platelet deposition, acute arterial thrombotic occlusion, thromboembolism, or stenosis in coronary, cerebral or peripheral arteries or in vascular grafts comprising an effective amount of isolated and purified activated protein C in an amount that provides a dose of 0.2 mg/kg-hr. to 1.1 mg/kg-hr. of activated protein C in a pharmaceutically acceptable carrier.
A pharmaceutical composition for inhibiting acute arterial thrombotic occlusion, thromboembolism, or stenosis in coronary, cerebral or peripheral arteries or in vascular grafts comprising an effective amount of isolated and purified activated protein C in a pharmaceutically acceptable carrier that provides an activated protein C plasma level in the range of 0.1 to 1.6 .mu.g/ml.
Dependencies are inferred from the claim text.